{"id":"any-platinum-based-doublet-chemotherapy","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Anemia"},{"rate":"50-70%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Platinum-based doublet chemotherapy involves the use of two platinum-based drugs, which form platinum-DNA adducts that prevent DNA replication and transcription, ultimately leading to cell death. This mechanism is particularly effective in rapidly dividing cancer cells.","oneSentence":"Platinum-based doublet chemotherapy works by interfering with DNA replication in cancer cells, ultimately leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:35.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Bladder cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT06788912","phase":"PHASE2","title":"Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Lung Neoplasm Malignant","enrollment":60},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT02129699","phase":"PHASE3","title":"Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy","status":"TERMINATED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2015-01-06","conditions":"Lung Cancer Non-small Cell Stage IV","enrollment":595},{"nctId":"NCT04606303","phase":"PHASE2","title":"A Phase Ⅱ Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy in Locally Advanced NSCLC.","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2020-12-18","conditions":"Locally Advanced NSCLC","enrollment":100},{"nctId":"NCT04042116","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor","status":"SUSPENDED","sponsor":"Clovis Oncology, Inc.","startDate":"2019-07-29","conditions":"Advanced Solid Tumor, Gynecologic Cancer","enrollment":227},{"nctId":"NCT02662634","phase":"PHASE2","title":"A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"GU Research Network, LLC","startDate":"2016-03","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT01772004","phase":"PHASE1","title":"Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2013-01-31","conditions":"Solid Tumors","enrollment":1756},{"nctId":"NCT01840579","phase":"PHASE1","title":"Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-26","conditions":"Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":57},{"nctId":"NCT02083679","phase":"PHASE1","title":"Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2014-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":15},{"nctId":"NCT01067794","phase":"","title":"Chemotherapy in Treating Patients With Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-04","conditions":"Non Small Cell Lung Cancer","enrollment":1610}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":301,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Any platinum-based doublet chemotherapy","genericName":"Any platinum-based doublet chemotherapy","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Platinum-based doublet chemotherapy works by interfering with DNA replication in cancer cells, ultimately leading to cell death. Used for Non-small cell lung cancer, Small cell lung cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}